A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women

Trial Profile

A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Nov 2015 Planned number of patients changed from 176 to 194 as per ClinicalTrials.gov record.
    • 11 Mar 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top